292 related articles for article (PubMed ID: 19047679)
21. Antagonism of B cell enhancer networks by STAT5 drives leukemia and poor patient survival.
Katerndahl CDS; Heltemes-Harris LM; Willette MJL; Henzler CM; Frietze S; Yang R; Schjerven H; Silverstein KAT; Ramsey LB; Hubbard G; Wells AD; Kuiper RP; Scheijen B; van Leeuwen FN; Müschen M; Kornblau SM; Farrar MA
Nat Immunol; 2017 Jun; 18(6):694-704. PubMed ID: 28369050
[TBL] [Abstract][Full Text] [Related]
22. Involvement of Blnk and Foxo1 in tumor suppression in BCR‑ABL1‑transformed pro‑B cells.
Zhang P; Wang Y; Qin M; Li D; Odhiambo WO; Yuan M; Lv Z; Liu C; Ma Y; Dong Y; Ji Y
Oncol Rep; 2021 Feb; 45(2):693-705. PubMed ID: 33416167
[TBL] [Abstract][Full Text] [Related]
23. Fms-like tyrosine kinase 3 ligand stimulation induces MLL-rearranged leukemia cells into quiescence resistant to antileukemic agents.
Furuichi Y; Goi K; Inukai T; Sato H; Nemoto A; Takahashi K; Akahane K; Hirose K; Honna H; Kuroda I; Zhang X; Kagami K; Hayashi Y; Harigaya K; Nakazawa S; Sugita K
Cancer Res; 2007 Oct; 67(20):9852-61. PubMed ID: 17942916
[TBL] [Abstract][Full Text] [Related]
24. Protein phosphatase 2A regulates interleukin-2 receptor complex formation and JAK3/STAT5 activation.
Ross JA; Cheng H; Nagy ZS; Frost JA; Kirken RA
J Biol Chem; 2010 Feb; 285(6):3582-3591. PubMed ID: 19923221
[TBL] [Abstract][Full Text] [Related]
25. Differences in phosphorylation of the IL-2R associated JAK/STAT proteins between HTLV-I(+), IL-2-independent and IL-2-dependent cell lines and uncultured leukemic cells from patients with adult T-cell lymphoma/leukemia.
Zhang Q; Lee B; Korecka M; Li G; Weyland C; Eck S; Gessain A; Arima N; Lessin SR; Shaw LM; Luger S; Kamoun M; Wasik MA
Leuk Res; 1999 Apr; 23(4):373-84. PubMed ID: 10229324
[TBL] [Abstract][Full Text] [Related]
26. Genome profiling revealed the activation of IL2RG/JAK3/STAT5 in peripheral T‑cell lymphoma expressing the ITK‑SYK fusion gene.
Zhang LL; Pan HX; Wang YX; Guo T; Liu L
Int J Oncol; 2019 Nov; 55(5):1077-1089. PubMed ID: 31545408
[TBL] [Abstract][Full Text] [Related]
27. Interleukin-7 promotes survival and cell cycle progression of T-cell acute lymphoblastic leukemia cells by down-regulating the cyclin-dependent kinase inhibitor p27(kip1).
Barata JT; Cardoso AA; Nadler LM; Boussiotis VA
Blood; 2001 Sep; 98(5):1524-31. PubMed ID: 11520803
[TBL] [Abstract][Full Text] [Related]
28. Infection Exposure is a Causal Factor in B-cell Precursor Acute Lymphoblastic Leukemia as a Result of Pax5-Inherited Susceptibility.
Martín-Lorenzo A; Hauer J; Vicente-Dueñas C; Auer F; González-Herrero I; García-Ramírez I; Ginzel S; Thiele R; Constantinescu SN; Bartenhagen C; Dugas M; Gombert M; Schäfer D; Blanco O; Mayado A; Orfao A; Alonso-López D; Rivas Jde L; Cobaleda C; García-Cenador MB; García-Criado FJ; Sánchez-García I; Borkhardt A
Cancer Discov; 2015 Dec; 5(12):1328-43. PubMed ID: 26408659
[TBL] [Abstract][Full Text] [Related]
29. Constitutive activation of JAK3/STAT3 in colon carcinoma tumors and cell lines: inhibition of JAK3/STAT3 signaling induces apoptosis and cell cycle arrest of colon carcinoma cells.
Lin Q; Lai R; Chirieac LR; Li C; Thomazy VA; Grammatikakis I; Rassidakis GZ; Zhang W; Fujio Y; Kunisada K; Hamilton SR; Amin HM
Am J Pathol; 2005 Oct; 167(4):969-80. PubMed ID: 16192633
[TBL] [Abstract][Full Text] [Related]
30. IL-7 reconstitutes multiple aspects of v-Abl-mediated signaling.
Banerjee A; Rothman P
J Immunol; 1998 Nov; 161(9):4611-7. PubMed ID: 9794389
[TBL] [Abstract][Full Text] [Related]
31. [Inhibition of constitutively activated Jak3 and induction of apoptosis in NALM-6 cell line].
Hu W; Zhang C; Zhang P; Wei D; Zhao Z; Cai M
Hua Xi Yi Ke Da Xue Xue Bao; 2002 Jan; 33(1):25-7. PubMed ID: 12599420
[TBL] [Abstract][Full Text] [Related]
32. The adaptor protein BLNK is required for b cell antigen receptor-induced activation of nuclear factor-kappa B and cell cycle entry and survival of B lymphocytes.
Tan JE; Wong SC; Gan SK; Xu S; Lam KP
J Biol Chem; 2001 Jun; 276(23):20055-63. PubMed ID: 11274146
[TBL] [Abstract][Full Text] [Related]
33. Interleukin-7 receptor α mutational activation can initiate precursor B-cell acute lymphoblastic leukemia.
Almeida ARM; Neto JL; Cachucho A; Euzébio M; Meng X; Kim R; Fernandes MB; Raposo B; Oliveira ML; Ribeiro D; Fragoso R; Zenatti PP; Soares T; de Matos MR; Corrêa JR; Duque M; Roberts KG; Gu Z; Qu C; Pereira C; Pyne S; Pyne NJ; Barreto VM; Bernard-Pierrot I; Clappier E; Mullighan CG; Grosso AR; Yunes JA; Barata JT
Nat Commun; 2021 Dec; 12(1):7268. PubMed ID: 34907175
[TBL] [Abstract][Full Text] [Related]
34. Concomitant inhibition of Janus kinase 3 and calcineurin-dependent signaling pathways synergistically prolongs the survival of rat heart allografts.
Behbod F; Erwin-Cohen RA; Wang ME; Trawick BW; Qu X; Verani R; Kahan BD; Stepkowski SM; Kirken RA
J Immunol; 2001 Mar; 166(6):3724-32. PubMed ID: 11238613
[TBL] [Abstract][Full Text] [Related]
35. Reconstitution of early lymphoid proliferation and immune function in Jak3-deficient mice by interleukin-3.
Brown MP; Nosaka T; Tripp RA; Brooks J; van Deursen JM; Brenner MK; Doherty PC; Ihle JN
Blood; 1999 Sep; 94(6):1906-14. PubMed ID: 10477719
[TBL] [Abstract][Full Text] [Related]
36. ZFP521 contributes to pre-B-cell lymphomagenesis through modulation of the pre-B-cell receptor signaling pathway.
Hiratsuka T; Takei Y; Ohmori R; Imai Y; Ozeki M; Tamaki K; Haga H; Nakamura T; Tsuruyama T
Oncogene; 2016 Jun; 35(25):3227-38. PubMed ID: 26522721
[TBL] [Abstract][Full Text] [Related]
37. Janus kinases in interleukin-2-mediated signaling: JAK1 and JAK3 are differentially regulated by tyrosine phosphorylation.
Liu KD; Gaffen SL; Goldsmith MA; Greene WC
Curr Biol; 1997 Nov; 7(11):817-26. PubMed ID: 9382798
[TBL] [Abstract][Full Text] [Related]
38. Activated Jak2 with the V617F point mutation promotes G1/S phase transition.
Walz C; Crowley BJ; Hudon HE; Gramlich JL; Neuberg DS; Podar K; Griffin JD; Sattler M
J Biol Chem; 2006 Jun; 281(26):18177-83. PubMed ID: 16632470
[TBL] [Abstract][Full Text] [Related]
39. Mutant JAK3 signaling is increased by loss of wild-type JAK3 or by acquisition of secondary JAK3 mutations in T-ALL.
Degryse S; Bornschein S; de Bock CE; Leroy E; Vanden Bempt M; Demeyer S; Jacobs K; Geerdens E; Gielen O; Soulier J; Harrison CJ; Constantinescu SN; Cools J
Blood; 2018 Jan; 131(4):421-425. PubMed ID: 29187379
[TBL] [Abstract][Full Text] [Related]
40. Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia.
Zenatti PP; Ribeiro D; Li W; Zuurbier L; Silva MC; Paganin M; Tritapoe J; Hixon JA; Silveira AB; Cardoso BA; Sarmento LM; Correia N; Toribio ML; Kobarg J; Horstmann M; Pieters R; Brandalise SR; Ferrando AA; Meijerink JP; Durum SK; Yunes JA; Barata JT
Nat Genet; 2011 Sep; 43(10):932-9. PubMed ID: 21892159
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
